Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider Losses - Has The Bull Case Changed?

In May 2026, Immunovant, Inc. reported a wider fourth-quarter and full-year net loss, with the quarterly loss reaching US$147.86 million and basic loss per share from continuing operations at US$0.73, while reiterating its cash position of about US$902.1 million to support development of its lead asset IMVT-1402. On the same day, Immunovant released encouraging Week 16 data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, showing strong response rates even in patients who had failed multiple advanced therapies, and announced it would discontinue batoclimab to concentrate resources on IMVT-1402 across several autoimmune indications. We’ll now examine how the strong IMVT-1402 rheumatoid arthritis data, alongside Immunovant’s sharpened pipeline focus, affects the company’s investment narrative.

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

Immunovant Investment Narrative Recap

To own Immunovant today, you have to believe IMVT-1402 can translate its early autoimmune data into approvals and meaningful use before cash and competition bite too hard. The latest Week 16 rheumatoid arthritis results and the decision to concentrate on IMVT-1402 arguably strengthen the near term catalyst around Graves’ disease and difficult to treat RA data, but they also highlight the key risk that rising R&D spending and ongoing losses could persist longer than some investors might prefer.

The most relevant recent announcement here is Immunovant’s fiscal 2026 update, which paired a wider annual net loss of US$505.61 million with US$902.1 million in cash and strong IMVT-1402 rheumatoid arthritis responses, including 72.7% ACR20 and 35.8% ACR70 at Week 16. That combination of deeper losses, solid funding, and a sharpened pipeline focus around a single FcRn asset frames both the opportunity and the execution risk around the upcoming IMVT-1402 readouts across multiple autoimmune indications.

Yet against the excitement around IMVT-1402, investors should be aware that the FcRn class is getting more crowded and...

Read the full narrative on Immunovant (it's free!)

Immunovant’s narrative projects $381.4 million revenue and $47.7 million earnings by 2029. This implies an earnings increase of about $511.9 million from -$464.2 million today.

Uncover how Immunovant's forecasts yield a $41.12 fair value, a 20% upside to its current price.

Exploring Other PerspectivesIMVT 1-Year Stock Price Chart

Before this news, the most cautious analysts were only penciling in about US$1.4 million of revenue and roughly US$0.2 million of earnings by 2029, so if you are using those assumptions you are effectively betting that even strong IMVT-1402 data and Roivant’s cash backing might not fully offset trial size, timing and pricing risks.

Story Continues

Explore 2 other fair value estimates on Immunovant - why the stock might be worth as much as 29% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

A great starting point for your Immunovant research is our analysis highlighting 5 important warning signs that could impact your investment decision. Our free Immunovant research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunovant's overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution. Find 53 companies with promising cash flow potential yet trading below their fair value. Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include IMVT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments